US Clinics Seek Early Access to New Pancreatic Cancer Drug
Cancer centers are rushing to enroll patients in an expanded access program for daraxonrasib after clinical trials showed the pill doubled survival rates. Revolution Medicines is working with the FDA to provide the treatment free of charge while awaiting a potential expedited regulatory approval.
Xurve View
Insights:
Xurve View
REVOLUTION MEDICINES INC is facing a surge in demand for its experimental pancreatic cancer drug following a survival-doubling clinical trial. The United States FDA authorized an expanded access program on May 1 to provide the oral pill, daraxonrasib, to patients with advanced disease. This early access bridge precedes a potential expedited approval that could finalize within months of a formal filing.
